Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Between Two Oral Tamsulosin Products in Healthy Male Subjects
NCT07698288Completed
- Sponsor
- Adium Pharma
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Adium Pharma. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Curve from Time Zero to Last Quantifiable Concentration. Started Feb 2026; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07698288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698288.